Description of Business and Unaudited Financial Statements	6 Months Ended
Dec. 31, 2011
Description of Business and Unaudited Financial Statements [Abstract]
Description of Business and Unaudited Financial Statements	1. Description of Business and Unaudited Financial Statements Unilife Corporation (collectively with its consolidated subsidiaries, the “Company”) and subsidiaries is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems. The primary target customers for the Company’s products include pharmaceutical and biotechnology companies seeking access to innovative, differentiated devices that can enable or enhance the administration of their injectable drugs and vaccines. Secondary customers also include suppliers of medical equipment to healthcare facilities and distributors to patients who self-administer prescription medication. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited consolidated financial statements contain all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented as required by Rule 10-01 of Regulation S-X. Interim results may not be indicative of results for a full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended June 30, 2011 contained in its Annual Report on Form 10-K. References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union.

Description of Business and Unaudited Financial Statements

6 Months Ended

Dec. 31, 2011

Description of Business and Unaudited Financial Statements [Abstract]

Description of Business and Unaudited Financial Statements

1. Description of Business and Unaudited Financial Statements

Unilife Corporation (collectively with its consolidated subsidiaries, the “Company”) and subsidiaries is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems. The primary target customers for the Company’s products include pharmaceutical and biotechnology companies seeking access to innovative, differentiated devices that can enable or enhance the administration of their injectable drugs and vaccines. Secondary customers also include suppliers of medical equipment to healthcare facilities and distributors to patients who self-administer prescription medication.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited consolidated financial statements contain all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented as required by Rule 10-01 of Regulation S-X. Interim results may not be indicative of results for a full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended June 30, 2011 contained in its Annual Report on Form 10-K.

References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union.